Omics-based profiling to find disease mechanisms and biomarkers in Alzheimer’s, Parkinson’s, FTD, and related dementias
Official title: Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases
Run by Ospedale Policlinico San Martino · NCT07235111 · Data updated 2026-11-12
This project will use advanced omics tests (genetics, gene expression, proteins, and metabolites) to try to find biological markers and disease mechanisms in people with Alzheimer’s, Parkinson’s, frontotemporal and young-onset dementias, or mild cognitive impairment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1200 (estimated) |
| Sponsor | Ospedale Policlinico San Martino Academic / other |
| Locations | 1 site (Genoa, Genoa) |
| Status | Recruiting |
| Started | February 28, 2025 |
| Main results expected | September 17, 2034 |
| Study ends | September 17, 2039 |
| Registry record updated | November 25, 2025 |
| Trial ID | NCT07235111 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults diagnosed with Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, Lewy body disease, young-onset dementia, or mild cognitive impairment who can consent and attend participating Italian centers are ideal candidates.
✕Probably not a fit
People without a diagnosed neurodegenerative disorder, those unable or unwilling to provide biological samples, or those seeking immediate therapeutic benefit are unlikely to gain direct clinical benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project will enroll at least 1,200 patients with Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, mild cognitive impairment, and young-onset dementia from major Italian centers. Researchers will collect peripheral biological samples and integrate genomic, transcriptomic, epigenomic, proteomic, metabolomic, and clinical data to more completely characterize disease pathways and identify candidate biomarkers. Participants are identified during routine outpatient visits and no investigational treatments are given. The aim is to discover markers useful for diagnosis, prognosis, monitoring, and predicting response to therapy.
Why it matters
Potential benefit: If successful, this work could enable earlier and more accurate diagnosis, better prediction of disease course and treatment response, and more personalized care for people with neurodegenerative diseases.
How similar studies have gone: Previous omics studies in neurodegeneration have identified promising candidate biomarkers and pathways, but large integrated datasets with clinical validation are still limited, so this approach is promising but not yet proven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria • Patients suffering from neurodegenerative diseases Exclusion Criteria • Patients not suffering from neurodegenerative diseases
Where it's running
-
Ospedale Policlinico San Martino
Genoa, Genoa, Italy Recruiting
Study contacts
- Study coordinator: Paola Mandich, MD, PhD
- Email: paola.mandich@unige.it
- Phone: +39 3473051001
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
A study on early diagnosis and biomarkers for dementia and related diseases
This study is testing new ways to spot dementia and related diseases early by looking for specific markers in the brain and body, to help people at high risk and track how well new treatments are working.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
-
OCT in Neurological Practice: Use of Retinal Layers to Help Diagnose and Follow Neurological Diseases
This study tests whether optical coherence tomography (OCT) of the retina can help in diagnosing and tracking multiple sclerosis, Alzheimer's, Parkinson's, migraines, and other headaches compared with healthy people.
-
Hyperspectral retinal imaging to detect Alzheimer’s and other neurodegenerative changes
This project will test whether a special retinal camera that scans many wavelengths of light can detect signs of Alzheimer’s and other neurodegenerative diseases in people with dementia or at risk.
-
Tongue-strengthening exercises for people with ALS
This program will test whether daily tongue-strengthening exercises can help people with ALS maintain or improve speech and swallowing.
-
Digital platform for early detection of Alzheimer-related memory impairment
The platform will be tested to see if combining EEG, eye-tracking, and blood flow sensors can detect early memory-related cognitive impairment in people aged 55–80.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.